There are urgent clinical, practical and economical needs for better performing artificial vascular grafts in CAB surgery.
ArtiFex Medical GmbH is a medical spin-off company originating from the University Hospital Basel. The company is developing a ground-breaking innovation for artificial vascular grafts that can be used for coronary and peripheral bypasses, as well as haemodialysis shunt surgery. ArtiFex Medical has perpetual exclusive rights to a unique patent portfolio originating at the University Hospital Basel. The technology is addressing a significant clinical problem in a €1.2 billion target market. The company is embedded in a world-class ecosystem of clinical and business professionals. Successful completion of the animal study will lead to a significant value inflexion point for the company